Bringing new treatments to patients faster and more efficiently. Formation Bio is an AI-native pharma company differentiated by radically more efficient drug development. The company has built proprietary technology platforms to optimize critical aspects of clinical drug development, enabling more efficient trial design, faster trial completion, and higher quality trial data. Formation Bio acquires clinical-stage drugs from pharmaceutical and biotech companies with the goal to develop assets faster, unlock greater value per program and ultimately accelerate access to new treatments for patients. 2025 CNBC Disruptor 50 2025 Fierce 15 Award 2024 Endpoints 11 Award

62 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

AOBiome is focused on transforming human health by developing microbiome-based therapies for inflammatory conditions. AOBiome Therapeutics, Inc. is a Cambridge, MA-based life sciences company focused on transforming human health by developing microbiome-based therapies for local, nasal and systemic inflammatory conditions. Founded in 2012 by PatientsLikeMe founder Jamie Heywood and MIT-trained Chemical Engineer David Whitlock, AOBiome is advancing a pipeline of multiple, clinical-stage therapeutic candidates. The company's portfolio includes multiple clinical-stage programs: a completed Phase 2 study to treat patients with acne vulgaris or acne, a Phase 1b study to treat patients with pediatric eczema (atopic dermatitis), a Phase 2a study …

67 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

TissueGen is a developer of next generation drug delivery technologies. TissueGen solves for unmet needs through the development of transformative drug delivery technologies that reduce treatment burden and improve clinical outcomes. We create life changing treatment modalities for patients and their caregivers, treating both acute and chronic conditions.

86 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing bacterial immunotherapies for oncology and infectious diseases. Microviable Therapeutics is a biotech company at pre-clinical stage, developing novel bacterial immunotherapies for oncology and AMR infectious diseases. Microviable was incorporated in 2016, as a spinoff of the Spanish National Research Council (CSIC). Microviable has received the European Seal of Excellence two times, a growing IP portfolio and numerous national and regional awards, and the certificate of Innovative SME. www.microviable.com Intestinal Microbiota, Intestinal disease, Clostridium difficile, Biotechnology, Microbiology, microbiota, microbiome, gut microbiota, gut health, probiotics, microbiota storage, microbiota isolation, GutAlive, anaerobes, human purified microbiota , biotherapeutics, and LBPs

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Harnessing the microbiome for the development of diagnosis and therapeutic tools in cancer ! EverImmune is a biotechnology company specialized in the development of live biotherapeutic products in the field of microbiota oncology. It harnesses the gut microbiota for the development of a unique approach aiming to restore the response of Immune Checkpoint Inhibitors (ICIs) in cancer patients. The company is developing Oncobax AK, a Live Biotherapeutic Product (LBP) used as an oral adjuvant to anticancer immunotherapies, designed to safely boost the immune system and restore sensitivity to immunotherapies in primary resistance settings. The company also develops other bacteria in …

123 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

LYMPHOGENiX is a leading company for lymphatic vessel regeneration research based in the UK and Japan operating globally LYMPHOGENiX is a UK-based biotechnology company focused on developing first-in-class therapeutics for infertility, leveraging a novel and underexplored biological system: the lymphatic vasculature. Infertility remains a major and growing global health challenge, affecting millions of individuals and couples worldwide. Despite advances in assisted reproductive technologies, implantation failure and poor endometrial receptivity continue to limit success rates. LYMPHOGENiX was founded to address this unmet need by targeting a fundamental but overlooked component of reproductive biology. Our core scientific insight is that lymphatic vessels …

62 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Developing mRNA vaccines and therapeutics In September 2021, Sanofi acquired Translate Bio, a clinical-stage mRNA therapeutics company. This acquisition further accelerates Sanofi’s efforts to develop transformative vaccines and therapies using mRNA technology. It adds a critical pillar to the company’s mRNA Center of Excellence, which aims to unlock the potential of next-generation mRNA vaccines and other strategic areas such as immunology, oncology, and rare diseases. Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We …

144 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Orikine Bio is a pioneering biotech company dedicated to advancing the field of engineered cytokines with unparalleled biological features for the treatment of immune-mediated diseases. Our core mission is to unlock the untapped potential of cytokines, enabling us to offer transformative therapies that have the power to reshape the lives of patients around the globe.

59 similar entities Type: Startup Activities: deeptech biotech

We are harnessing the biology of human aging to develop novel targets and therapies for metabolic diseases. BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The Company's lead product candidate, BGE-102, is a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed for cardiovascular risk and retinal diseases. A Phase 1 SAD/MAD trial of BGE-102 is underway, with topline data including additional MAD cohorts anticipated in 1H26. The Company is also developing long-acting injectable and oral small molecule APJ agonists for obesity. BioAge’s additional preclinical programs, which leverage …

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Leading the Next Frontier of Cell Therapy Sonoma Biotherapeutics is a South San Francisco and Seattle-based clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases by restoring balance to the immune system. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies. Sonoma Bio has initiated two Phase 1 studies to evaluate the safety and proof-of-mechanism of the company’s lead Treg cell therapy candidate, SBT-77-7101, in patients with rheumatoid arthritis and hidradenitis suppurativa. …

129 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Innovation for patient safety & environment PlasmaBiotics is an innovative company that was founded in 2011 and located in Paris, France. The core focus of Plasmabiotics, addressed through its core products, the PlasmaTYPHOON, and the AquaTYPHOON, is to increase the efficiency of hospitals and to minimize the risk of bacterial contamination. For more information, please visit https://www.plasmabiotics.com.

87 similar entities Type: SMB Activities: healthtech deeptech Technologies: SaaS

Life, reimagined. Constructive Bio designs and manufactures proteins with chemistries that don't exist in nature. By rewriting the genetic code, we give cells access to entirely new chemical building blocks, then scale what we find into medicines and materials that couldn't exist before. Our BioForge platform turns advanced molecular designs into manufacturable reality: complex peptides, site-specific conjugates, covalent biologics, and oral therapeutics that conventional synthesis cannot reliably produce. Constructive and its partners shift the question from "can we make this?" to "what should we make next?". Synthetic Biology, Genome engineering, Biopolymers, Protein engineering, Therapeutics, Biomanufacturing, and Genetic code expansion

77 similar entities Type: Startup Activities: it services deeptech Technologies: Synthetic Biology

Pioneering next-generation antibody therapies with AI and computational protein design Archon is a biotechnology company developing computationally designed proteins to unlock powerful therapeutic targets that lie beyond the reach of existing modalities and to better treat disease. We directly apply generative protein design to create a new biologic class, Antibody Cages (AbCs), that integrates the industry-proven affinity and specificity of antibodies into self-assembling nanostructures. Precise control over AbC structure provides the ability to tune both how they distribute in the body and engage their cellular targets with high specificity and potency to establish a new gold-standard for biologic medicines. Archon …

83 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Revolutionizing Cell Therapy with Protein Design Outpace is creating cell therapies with curative potential through protein design and cellular engineering. With an initial focus on solid tumors, Outpace is developing technologies that overcome the barriers to efficacy and safety by programming cells to make the right decisions inside patients. Outpace’s suite of technologies drive persistent activity of the cell therapy (OutLastTM), recruit a productive immune response in the tumor microenvironment (OutSmartTM), and achieve the potency (OutSpacersTM), specificity (Co-LOCKRTM), and safety (EGFRoptTM) necessary to unlock diverse cancer indications. Outpace’s internal and partnered pipeline approach is optimized for rapid clinical validation of …

61 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

The first homogeneous immunoassay platform offering unmatched sensitivity with scalable simplicity. Spear Bio, founded in 2021, is a well-funded and rapidly growing start-up headquartered in Woburn, Massachusetts. Spear Bio’s proprietary technology, Successive Proximity Extension Amplification Reaction (SPEAR), employs a unique 2-factor authentication mechanism to precisely measure protein biomarkers at attomolar levels from sub-microliter sample volumes, enabling unprecedented sensitivity. We are dedicated to revolutionizing early disease diagnosis and monitoring, empowering clinicians and researchers to improve patient outcomes, and advance global health. For more information, please visit www.spear.bio or email info@spear.bio. Biotechnology, Ultra Sensitive Immunoassays, and research

203 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

‘Off-the-Shelf’ Curative Cell Therapies About Us: Cell BioEngines is a US-based clinical-stage biotechnology company developing off-the-shelf allogeneic cell therapies by chemically reprogramming stem cell fate and function to treat serious and currently incurable diseases. Leveraging cord blood stem cells from highly compatible 'super-donors' and powered by its proprietary STEM-Space cellular reprogramming platform, the company delivers scalable cell products with reduced risk of immune rejection. Cell BioEngines’ competitive edge comes from a unique combination of a transgene-free scalable manufacturing platform enabled by advanced chemical reprogramming, rigorous HLA-guided design, and a population-informed biobank that supports broad patient coverage. Cell BioEngines lead clinical …

311 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Powering New Possibles in Cell Therapy Manufacturing Cell therapy has transformed cancer treatment, yet the hurdles of manufacturing patient-derived cell therapies remain a formidable challenge for the industry. Quality and scalability problems lead to high therapeutic costs and limit access to those life-saving treatments. By harnessing the power of cutting-edge semiconductor technologies, including silicon photonics seamlessly integrated into microfluidic cartridges, Sarcura is orchestrating a transformative shift. Central to Sarcura's mission is the creation of fully automated manufacturing systems endowed with real-time process and product control. This pioneering platform promises to usher in a new era of cost-effective and secure cell …

68 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Targeting Beta Cell recovery in Diabetes DiogenX is a preclinical stage biotech company committed to a single mission: to discover and develop innovative biologics as new therapeutics options for millions of Diabetic patients around the world. Our lead program, originating from Dr Patrick Collombat’s laboratory, is based on a new approach targeting beta-cell failure throughout the stimulation of beta-cell functional recovery in diabetes. This novel mode of action will provide a unique solution to rebalance glucose/insulin homeostasis and thus offer clear clinically meaningful benefits. DiogenX is headquartered in Marseille, with labs in Nice (France). Biotechnology and Diabetes

66 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

BariaTek is a clinical stage company dedicated to treating obesity via a reversible non-invasive endoscopic approach. BariaTek Medical is a clinical stage company dedicated to addressing obesity via minimally invasive endoscopic approaches. Obesity is one of the most debilitating pandemics affecting humanity: More than 2 billion people are overweight of which 1 billion suffer from obesity. People suffering from obesity tend to lead shorter, less healthy, lives. Treating overweight-related conditions (diabetes, hypertension, sleep apnea and others) is projected to cost G-20 nations on average 8.7% of their health budgets over the next three decades which is estimated by the United …

60 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Clinical stage biotechnology company whose vision is to be a trusted and acknowledged leader in the microbiome field. Da Volterra is a clinical stage biotechnology company whose vision is to be a trusted and acknowledged leader in the microbiota field. Our mission is to discover, develop and bring to market safe and novel therapeutic options, preserving patients’ microbiota to prevent and cure life-threatening diseases. We strive to serve patients by transforming the promise of science into innovative treatments which have the power to improve health and save lives.​ Committed to innovation, Da Volterra develops products intended to protect the intestinal …

89 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Developing the next generation bacterial cancer therapy Developing the next generation bacterial cancer therapy The vision of T3 Pharmaceuticals is to improve the lives of cancer patients with highly innovative treatments. Despite significant advances of classical therapies, there remains a high need for novel and innovative medicines to treat cancer. T3 Pharmaceuticals is dedicated to fill this gap by developing highly specific and efficient treatments using live bacteria. T3 Pharmaceuticals was founded in May 2015 by Simon Ittig, Christoph Kasper, Marlise Amstutz and Helmut Kessmann as a spin-off of the University of Basel. The team has developed an efficient protein …

94 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Inventing a new class of medicines using Targeted Protein Degradation Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on delivering oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of …

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Science of certainty Gubra is a biotech company built on three synergistic business units, Biotech, CRO Services, and Ventures, united by a commitment to scientific excellence, strong partnerships, and responsible impact. ESG principles are embedded in our business model, including Gubra Green, our subsidiary that allocates 10% of pre-tax profits to support a net-zero, nature-positive future. Founded in 2008, Gubra has grown from a metabolic research specialist into a diversified organization of more than 300 scientists and experts. Today, we advance proprietary therapeutic programs, deliver high-end preclinical research services to global partners, and create new drug discovery opportunities through agile …

118 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Advancing cancer care through microbiome profiling 🦠 Discover your microbiome: www.mybioma.com Biome Diagnostics GmbH (BiomeDx®) is an Austria-based MedTech company driving precision medicine through pioneering microbiome-based technologies that transform cancer care. At the intersection of state-of-the-art DNA sequencing and advanced machine learning, BiomeDx® develops first-in-class solutions for routine clinical practice. In addition to the lifestyle product myBioma (www.mybioma.com) for end-customers, the company focuses on medically certified products in the fields of gut microbiome and cancer. With ISO 9001 and ISO 13485 certifications, BiomeDx® is the first microbiome company worldwide with dual ISO certification — reflecting our commitment to safety and …

79 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology A.I. A.I. - Machine Learning

Global experts in nanotechnology and drug particle engineering Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform’s platform technologies. The company focuses on reducing clinical attrition and on enhancing drug molecules’ performance through its nanoforming technologies and formulation services. Nanoform’s capabilities include GMP manufacturing, and its services span the small to large molecule development space with a focus on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications.

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing tomorrow's cancer therapies. Today. invIOs is a private biotech company focusing on discovery and development of novel cancer therapeutics that empower and educate the immune system to fight cancer. We leverage our deep expertise in immune-system activation to advance a focused pipeline of individualized and targeted approaches against solid tumors. Our focus is on earlier-stage development, with a sweet spot in bringing assets through discovery and pre-clinical development and into clinical trials. We launched in 2022 as a spin-out bundling the innovative oncology assets of APEIRON Biologics. Our highly motivated team of 35 people has deep expertise across the …

372 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Eveliqure Biotechnologies is developing novel vaccines for the prevention of diarrhoeal diseases. Eveliqure Biotechnologies is an innovative biotech company developing novel vaccines for the prevention of diarrhoeal diseases both for travellers and people living in endemic regions of low- and middle-income countries. Eveliqure is a game-changer amongst vaccine companies, championing novel technologies to make the world safe from diarrhoea. Eveliqure is passionate about improving the quality of life for both the poor and the privileged by providing innovative medical solutions that fight diarrhoeal diseases.

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneers in nanotechnology-based cancer treatment MagForce is forging new paths to treat cancer successfully and gently. With NanoTherm® Therapy System (NTTS), we have developed an innovative approach based on nanotechnology, which we want to make available to patients worldwide. And we are getting closer and closer to this goal. NTTS is the first and only nanotechnology-based therapy with European approval for treating recurrent Glioblastoma, a deadly brain tumor. To date, many patients diagnosed with Glioblastoma tumors have improved their quality of life after using our technology. Nanomedicine, Oncology, Brain Tumor, Nanotechnology, Glioblastoma, Prostate Cancer, Medical Devices, Medical Technology, and Thermotherapy

73 similar entities Type: SMB Activities: healthtech deeptech nanotech biotech Technologies: Synthetic Biology

Streamlining nanoparticle formulation to release the full power of RNA-LNPs and nanomedicines. InsideTx streamlines RNA-LNP formulation from screening to manufacturing. Founded at the intersection of microfluidics and biotechnology, we build formulation platforms that cover the full RNA-LNP & nanomedicine development pipeline — so researchers can focus on the science, not the process. TAMARA is our all-in-one R&D platform for nanoparticle formulation. It handles everything from early screening to preclinical in-vivo studies in a single instrument (0.2–30 mL), with zero formulation losses, reusable microfluidic chips, and two mixing geometries on one reversible chip. As one of our users put it: "I'm …

85 similar entities Type: Startup Activities: manufacturing nanotech deeptech biotech Technologies: Synthetic Biology SaaS

A Microbiota biotherapeutics and Vaccines company. Conditioning the gut ecosystem for disease prevention and therapy. Spin-off from the Institute for Research in Biomedicine (IRB) in Bellinzona, Switzerland, aimed at shaping the intestinal microbiota for the cure and prevention of diseases such as bowel diseases and cancer. The gut ecosystem conditions the function of all our organs and plays a fundamental role in our wellbeing. The mucosal immune system has co-evolved with the intestinal microbiota to adapt its function to a number of environmental and possibly pathogenic factors. MV Bio leverages a microbiota-mediated mechanism regulating the physiological response of the intestinal …

55 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Leading the Microbiome revolution Seres Therapeutics is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Our lead program, VOWSTTM, obtained U.S. FDA approval in April 2023 as the first orally administered microbiota-based therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science. We are evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce incidences of gastrointestinal infections, bloodstream infections, and graft-versus-host disease as well as additional preclinical stage programs targeting Infection Protection in …

137 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Science to Transform Lives Immunocore is a leading T cell receptor (TCR) biotechnology company working to create first-in-class biological therapies to address unmet patient needs in oncology as well as infectious and autoimmune diseases. See our community guidelines: http://bit.ly/2kFA8hr Biotechnology, Cancer, Oncology, Infectious Diseases, Autoimmune Diseases, T Cell Receptor, Immunotherapy, ImmTAX, ImmTAC, ImmTAV, and ImmTAAI

267 similar entities Type: Startup Activities: deeptech hrtech biotech Technologies: Synthetic Biology

Single-Molecule Analysis. Revolutionizing Medical Research. UNOMR AG, a techBio startup from ETH Zurich, is pioneering single-molecule protein sequencing through their innovative interface nanopore sensor, currently with a focus on site-specific posttranslational modification analysis. UNOMR's patented solution has far-reaching applications across healthcare, pharmaceutical development, and food science, offering a powerful new tool for therapeutic discovery and medical food product innovation. Driven by the vision of bringing advanced proteomics directly to the patient, UNOMR aims to catalyze the next breakthrough in precision medicine by making sophisticated protein analysis accessible.

60 similar entities Type: Startup Activities: deeptech it services Technologies: Synthetic Biology

Better Biologics Through Chemistry Bright Peak are developing a portfolio of first-in-class and best-in-class cytokines with optimized biological properties for the treatment of cancer and autoimmune diseases. Through a variety of proprietary technology platforms, Bright Peak is uniquely abled to conjugate its cytokines as payloads to antibodies, creating bespoke, novel and proprietary “Bright Peak Immunocytokines”, and to other cytokines as “duokines”. The Bright Peak Immunocytokines allow tissue- and cell-specific targeting of the cytokine payload with the added potential for significantly enhanced efficacy. One of the many advantages of our approach is its "off-the-shelf" feature. Using a pioneering site-specific ADC-like chemical …

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Crescendo Biologics - The T cell Enhancing Company Crescendo Biologics is a private, clinical stage immuno-oncology company developing novel, targeted T cell enhancing Humabody® therapeutics. Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel half-life extended CD137 x PSMA Humabody for the selective activation of tumour-specific T cells exclusively within the tumour microenvironment. CB307 is designed to achieve a longer lasting anti-cancer effect whilst avoiding systemic toxicity, and the clinical programme for CB307 is underway in patients with PSMA positive solid tumours (NCT04839991). CB693 is a half-life extended CD137 x MSLN Humabody and is the second proprietary clinical …

82 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

For every therapeutic challenge, we question traditional assumptions and find better solutions. VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immunological (I&I) conditions with high unmet need. Led by a proven and resourceful team of drug developers, VYNE is applying scientific innovation to advance novel therapies that have the potential to improve the lives of millions of people afflicted by autoimmune diseases. The catalyst of the company’s differentiated approach is its proprietary InhiBETTM Platform that potentially unlocks a promising new drug target for improving the treatment of challenging I&I diseases with …

90 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Treating the individual, not just the disease, through personalized and optimized dosing. We need to shift to a world where we treat the individual, not just the disease. Our inventions work in combination with medicine to deliver personalized, optimized dosing, to provide bespoke universal healthcare access and improve outcomes for patients with chronic diseases. Closed Loop Medicine is a TechBio company developing combination prescription drug + software products, with the aim of bringing forward the promise of precision care. Our proprietary technology platform facilitates personalized drug dose optimization through integration of medicines and software with patient-led digital experiences and closed …

85 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

We are unlocking pathways to be. We are Compass, a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. We believe people living with mental health conditions deserve the possibility of a better future. Our initial focus is advancing COMP360, a proprietary, investigational synthetic psilocybin treatment being evaluated for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). Our goal is to advance treatments that move the field of psychiatry towards treatment options that offer rapid onset and sustained durability, with infrequent dosing. We’re driven by our purpose of unlocking pathways to be—opening futures filled with …

72 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Biologics of a New Generation to Treat Allergy ANGANY is a private, early clinical stage pharmaceutical company, based in Lévis, QC, Canada. ANGANY has tackled the specific challenges of allergy to invent a novel class of biologics. ANGANY has developed an exclusive therapeutic platform based on synthetic biology: the eBioparticle TM, a self-adjuvant vector bringing novel features of safety and potent immunomodulation to thwart allergy.

62 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Enabling manufacture of cell therapies at scale Cell therapy manufacturing was never designed to scale. Cellular Origins is changing that. We enable the manufacture of cell therapies at commercial scale through a flexible, factory-led approach. Our platform, Constellation, combines mobile robotics and AI to orchestrate the movement of patient material, equipment, and processes across the entire facility, while integrating with your leading bioprocessing technologies. By replacing fixed, linear systems with modular, parallelisable design, we enable intelligent capacity planning, built-in redundancy, and seamless scale-up without process redesign. The result is lower risk, greater efficiency, increased flexibility, and a faster path to …

111 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Laigo's SureTAC platform enables rapid therapy development for removal of disease-driving membrane proteins #laigobio Laigo's proprietary SureTAC platform empowers us to rapidly develop first-in-class dual targeted therapies that eliminate disease-driving membrane targets using straightforward bispecific antibody technology. We are committed to exploring an ever-evolving universe of new targets, including those currently considered undruggable, and we are open to strategic partnerships to make meaningful advancements in treating diseases that lack effective treatment options today. Laigo Bio is where innovation meets life-changing solutions, forging a path toward a healthier tomorrow. #TPD #Protac #membraneprotein #bispecificantibody #antibody #proteindegradation #roteindegrader #LaigoBio #oncology #neurobiology #immunology #SureTACs

146 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Better Science, Better Health 🧬 The OptiBiotix difference; improving health and wellbeing. OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease. The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes. OptiBiotix has established a pipeline of …

61 similar entities Type: Startup Activities: healthtech deeptech Technologies: SaaS

Delivering the promise of radiopharmaceuticals to patients. PASSION FOR PRECISION. ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including multiple Phase 3 studies, combining the company’s high-quality radioisotopes with a range of targeting molecules. By leveraging our two decades of pioneering radiopharma expertise, central industry position and …

118 similar entities Type: SMB Activities: manufacturing biotech deeptech Technologies: Synthetic Biology

The purpose of Idorsia is to discover, develop, and commercialize innovative medicines to help more patients. We have more ideas, we see more opportunities, and we want to transform the horizon of therapeutic options. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core. Headquartered in Switzerland – a biotech-hub of Europe – Idorsia is a high-potential biopharmaceutical company, specialized in the discovery, development and commercialization of innovative small molecules, with the aim of transforming the horizon of therapeutic options. See our LinkedIn community guidelines: https://bit.ly/4nAfOZp Idorsia privacy policy: https://www.idorsia.com/legal/privacy-policy

61 similar entities Type: Startup Activities: biotech Technologies: Synthetic Biology

Giving Life to Science PureTech Health is a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value. We do this through a proven, capital-efficient R&D model focused on opportunities with validated pharmacology and untapped potential to address significant patient needs. This strategy has produced dozens of therapeutic candidates, including three that have received U.S. FDA approval. By identifying, shaping, and de-risking these high-conviction assets, and scaling them through dedicated structures backed by external capital, we accelerate their path to patients while creating sustainable value for shareholders. For more information, visit www.puretechhealth.com or connect with us …

182 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Accelerating biomedical research by connecting biopharmas with the right preclinical cancer models and CRO partners Repositive is committed to accelerating the development of precision cancer therapies to the clinic by working with biopharmas and Contract Research Organisations (CROs) to improve the predictivity of pre-clinical cancer research. Through its Cancer Models Scout service, Repositive is helping biopharmas to optimise their pre-clinical cancer projects by identifying the most suitable cancer models for their requirements from its world-leading database of over 8000 models, as well as via outreach to an extended network of CRO contacts. Repositive works to connect researchers with the right …

130 similar entities Type: Startup Activities: biotech it services deeptech Technologies: Synthetic Biology

BioCopy is a Swiss-German biotech company with headquarters in Basel and a state-of-the-art R&D facility in Emmendingen, Germany. The company focuses on drastically accelerating the development of safe and effective next-generation cancer drugs to improve the chance of a cure significantly. BioCopy combines artificial intelligence with its automated end-to-end engineering platform to create biotherapeutics with unrivalled efficacy and safety that are transforming the R&D process in today's pharmaceutical industry. The BioCopy platform generates data sets of high quality and quantity currently unmatched in the industry that are essential to leverage the potential of AI. This synergy reduces the research and …

402 similar entities Type: Startup Activities: deeptech Technologies: A.I. Synthetic Biology

Let's Build Better Cells Together At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQureTM gene editing risk assessment services enable high-performance cell engineering and rigorous evaluation of editing outcomes, supporting confidence in therapeutic development. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we’ve been advancing cell engineering, shaping …

334 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Using mesenchymal stem cells to produce therapeutically meaningful extracellular vesicles. We are a recently incorporated limited company, spun out from the University of York from the Genever lab (www.geneverlab.info), which has over 20 years of experience in cell biology and regenerative medicine. We focus on musculoskeletal regeneration using mesenchymal stem cells (MSCs), with a view to translate our body of work into cutting edge therapeutics. Our current focal point is the field of extracellular vesicles (EVs), which have recently gained substantial traction as a next-generation therapeutic modality. We believe that current approaches have room for improvement in terms of consistency …

93 similar entities Type: Startup Activities: biotech healthtech Technologies: Synthetic Biology

Changing the future of cancer care by accurately predicting patient response to therapies before treatment begins Kiyatec is disrupting cancer care by accurately predicting patient–specific response and non–response before treatment begins. We utilize the patient’s own living tumor cells to create functional 3D models to test a battery of cancer therapies in our CLIA-certified and research laboratories. Our goal is to enable physicians to isolate only the effective treatments for their patients as quickly as possible - making true personalized medicine a reality. Our approach has been validated through engagements with leading cancer hospitals, multiple top 10 pharmaceutical companies and …

281 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We develop treatments to give hope back to patients. Tratamientos que devuelven la esperanza a los pacientes. We are a biotechnology company that develops effective and safe therapeutic treatments for cancer with the purpose of restoring hope to patients who have no other option. We have been studying cancer and especially its relationship with inflammation for more than 7 years. Somos una empresa biotecnológica que desarrolla tratamientos terapéuticos eficaces y seguros contra el cáncer con el propósito de devolver la esperanza a pacientes que no tienen otra opción. Llevamos más de 7 años estudiando el cáncer y especialmente su relación …

96 similar entities Type: Startup Activities: healthtech deeptech biotech Technologies: Synthetic Biology

PBD Biotech develops Actiphage, a blood test for human tuberculosis, bovine tuberculosis and Johne’s Disease. PBD Biotech develops Actiphage, a blood test that detects live Mycobacteria, the cause of tuberculosis (TB) in humans and bovine TB and Johne's Disease in animals. One quarter of the world’s population is infected with latent tuberculosis (LTBI), and for one in ten of these people it will progress to active TB disease. As Actiphage detects the presence of active infection, it has potential for a screening test for the disease and to improve drug management. Mycobacteria also cause the diseases bovine TB and Johne's …

57 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Precision-Guided Therapeutics Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company that is harnessing the power of bicyclic peptides and leveraging Nobel Prize-winning science to develop a new and differentiated class of medicines to treat cancer and other diseases. Bicycle® molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating zelenectide pevedotin, previously BT8009, a Bicycle® Toxin Conjugate (BTC®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC …

60 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Generate human-specific efficacy and safety data with PhysioMimix® microphysiological systems. CN Bio is a leading Organ-on-a-chip (OOC) company that enables scientists to improve the accuracy and efficiency of preclinical drug discovery. Our PhysioMimix® Core microphysiological system, 3D-validated cells, consumable plates, and Contract Research Services facilitate the prediction of human responses to drug exposure, in the presence or absence of disease, so that new medicines can be brought to market more rapidly, cost-effectively and using fewer animals. Utilizing primary cells, our perfused single (Lung, Liver), and multi-organ (Gut/Liver, Lung/Liver) models recapitulate the microarchitecture, microenvironment, and function of their human counterparts in …

202 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Guiding clinicians towards personalized treatment and enhancing quality of life for patients Using molecular structures to choose the best therapy. Currently focusing on mutations in EGFR and other lung cancer drivers. Working closely with the Molecular Tumor Board at the UMCG #umcg and patient organizations across Europe.

82 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Novel treatment paradigm for infertile women. Through targeting of the early and hormone-independent phase of egg maturation, we aim at developing a first-in-class treatment for infertile women, who do not benefit from standard hormone therapy.

63 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Mereo BioPharma is a clinical-stage company focused on developing & commercialising rare disease & oncology treatments. Welcome to Mereo BioPharma, we are an agile biopharmaceutical company, focused on finding and bringing to market therapies that will improve the lives of people living with a rare disease. We are driven by a true understanding of the critical nature of our mission. We harness the power of science; with our knowledge of the rare diseases we seek to treat and deep relationships with all our stakeholders to create new therapeutic possibilities for people who need them. We do this in a focused …

278 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Independent medical biology laboratory carrying out analyzes of blood and various biological fluids. Group of independent medical biology laboratories, BCH (Biology of the Heart of Hérault), located in Hérault. Its objective is to offer patients and healthcare professionals (prescribers, liberal nurses and correspondents) PROXIMITY and quality biology, in complete independence. Analyzes are carried out directly on site, allowing results to be delivered quickly and adapted to your care.

60 similar entities Type: Startup Activities: healthtech deeptech

Biotech specialized in the design of new medicine. Let's connect to know more about us ! At Aceso, we leverage our technology platform to explore new molecular pathways and develop strategic approaches aimed at redefining standards of care where existing therapies are insufficient. In the development of a new therapy for cystic fibrosis, Aceso is starting with ATC-101, its most advanced program designed to address the limitations of current treatments. Supported by robust proof-of-concept data and promising preclinical evidence, we are advancing toward IND-enabling studies, with entry into clinical trials as the next major milestone. With a science-driven roadmap and …

266 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

FROM DISCOVERY TO THERAPEUTICS MT-act is a CNRS spin-off. #techtransfer We develop class compounds to treat human pathologies that share a common molecular defect; dysfunction of the skeleton of the cells called microtubules - abbreviated MT. Stiffening of the skeleton of our cells is a central disease driver. That is why we act on them. We developed a technology platform to charter an entirely neglected pharmaceutical space. MT-act prioritizes indications based on scientific evidence, proven unmet medical needs and where the roadmap to patients is feasible and desired. Drug development, Microtubules, Tubulin code, Preclinical, Drug screening, first-in-class, and drug discovery

153 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Leading biotech in the development of innovative microbiome-based biotherapies YSOPIA Bioscience is a clinical-stage biotech company developing cutting-edge biotherapies based on the gut microbiome. Our goal is to bring safe & efficient solutions to patients with high unmet medical needs. Microbiome, Obesity, Gut modulator, Cardiometabolism, Cardiometabolic diseases, Microbiota, and Gut microbiota

298 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Revolutionizing healthcare with exosomes focusing on gastrointestinal, liver and kidney regeneration EverZom is an exosome biotech company developing treatments for digestive tissue healing like Crohn's fistula and organ regeneration like the kidney and the liver. Founded in 2019, EverZom is positioned to become the leader of exosome therapeutics, the next wave of innovation for the biotech industry. Exosomes, small vesicles secreted by cells, are increasingly recognized as potent agents for intercellular communication and play a crucial role to treat a wide range of diseases. Winner of the European EIC Accelerator Program, EVerZom aims to be the upcoming pioneer in this …

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

🖇️ Oncofactory, a spin-off of the CNRS, is a science-driven biotech company that provides pharmaceutical and biotech companies with innovative in vivo services to support their non-clinical programs in oncology. Oncofactory joined the ERBC Group in December 2022 to extend its technology to a wider range of customers and provide a one-stop shop for non-clinical studies. 🥚Oncofactory unique technology platform is a New Approach Methodology (NAM) to generate patient tumor replicas in avian embryos (AVI-PDXTM), coupled with state-of-the-art 3D imaging and large-scale molecular analysis for rapid assessment of therapeutic efficacy and in-depth characterization of mechanisms of action to evaluate therapeutic …

63 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Bringing People & Ressources Together The creation of Genbiotech, a spinoff of the Laboratoires Genévrier results of 15 years of strategic involvement in biotechnological research with one goal: to improve the quality of life of patients in the field of rheumatology, dermatology and aesthetic. We believe that tomorrow medicine needs to be dedicated and targeted to patients. We aim to improve existing treatments by using non invasive processes allowing local and sustained administration of biological and active molécules. The company, incepted in 1998, has currently a staff of 11 people and is located in Sophia Antipolis (South of France). For …

633 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Sharp understanding of the hardest things At Sagacity Health, we discover new horizons in oncology by merging Agentic AI with Biotech to decode the secret world inside tumors - turning unseen ecosystems into the next frontier of precision therapeutics. Our main objective is to bridge groundbreaking science, clinical partnerships, and industrial-scale innovation to bring first-in-class therapies from lab to patient. This is not just drug development; it is a paradigm shift in how we fight cancer.

265 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology A.I.

Advanced therapies inspired for you Defymed is a French SME that develops innovative medical devices aimed at treating patients physiologically in order to improve the clinical effectiveness of their treatment as well as their comfort. Defymed is a spin-off of the Centre européen d’étude du Diabète (European center for diabetes studies), which began work on a bioartificial pancreas in 1996. Today, Defymed focuses on diabetes, which is considered to be one of the major epidemics of the 21st century. There are currently two medical devices being developed by Defymed which are at an advanced preclinical trial phase: - #MailPan®: bioartificial …

59 similar entities Type: Startup Activities: healthtech biotech deeptech Technologies: Synthetic Biology

We make clinical approach rapid and easy Linking human metabolism to cell biology What: The methodology that we have developed within our academic laboratory makes it possible to quickly and directly obtain scientific data from humans to define the potential health benefit of a nutritional product, diversify and reposition an accredited drug or even search for and validate biomarkers of interest. Why: Created in March 2020, Clinic’n’Cell is a spin-off from our INRAe/University Clermont Auvergne academic laboratory which aims to simplify the obtaining of scientific data in humans to mark out your clinical investigations or simply boost your scientific marketing. …

126 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Unlocking New Immunotherapy Paths with Smart Peptides SPIMA Therapeutics emerges as a spin-off from the University of Montpellier, France, uniting experts in cutting-edge peptide chemistry and inflammation biology. SPIMA focuses on developing innovative peptide-based immunotherapies for challenging targets, particularly protein-protein interactions. Our lead program is a Stapled Peptide targeting the Myddosome complex. This innovative approach holds immense promise for revolutionizing treatments in inflammatory and oncological diseases, offering hope where it's needed most. SPIMA Therapeutics is part of the nexus of Landmark Bioventures. Join us in shaping the future of medicine, where discovery meets dedication. Immunothery

85 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Nanomaterials as Nanomedicines: let's play collective! SUPERBRANCHE : Nanomedicine as a breakthrough to treat cancer We bring answers to the following issue: intratumoral injection of nanomaterials implying both accessibility and detection of the tumor beforehand. We position ourselves as a producer dedicated to the synthesis of architectured nanomaterials as simple as possible and of controlled size. Our modular technology platform presents both therapeutic and diagnosis applications. It consists in a magnetic nanoparticle coated by a tailor made branched architecture. Thanks to their optimized shape and stability, our compounds are well tolerated and can be administered intravenously, thus helping to the …

78 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Creative Technologies for Efficient Therapeutics, Precision medicine Inoviem Scientific is a private Bioanalytical company which delivers enabling information to secure drug discovery programs and to take informed decision by closing the gap between preclinical and clinical development. We reconcile translational pharmacology and human physiology by using fresh patient material from the target cohort, embracing the complexity of human diseases. Inoviem's enabling technologies are working in pathological conditions to get the treatment in development to the right patient. Our indication-agnostic access to patients combined with innovative label-free platforms deliver Target identification and validation, targets & Mode of Action deconvolution, patient stratification, …

196 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We produce customised chemical proteins to help our bio-pharms partners to accelerate their projects. 🧪 X’PROCHEM is a biotech company who invented an advanced and proprietary ligation technology. We help our bio-pharma partners design and create therapeutic, vaccine and diagnostic proteins. Unlike recombinant fermentation we can produce proteins containing up to 400 amino acids, without isoforms, endotoxins, or biological contaminants. We co develop solutions with our partners to understand the real needs within the context. By working closely, we can adapt to changing needs and circumstances. protein, purification, synthesis, protein production, peptide synthesis, and life sciences

147 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Targeting protein interactions for health Founded in 2023, TheraPPI Bioscience is a biotechnology company whose science originates from the CRCL (Centre de Recherche de Cancérologie de Lyon, France). We modify protein interactions to offer treatments where current therapies fail. Our approach represents a paradigm shift in tackling cancer resistance and non-curable rare diseases protein-protein interaction, PPI, small molecule, therapeutics, oncology, and rare disease

216 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

At Nūmi, we're on a mission to redefine infant health through groundbreaking research and innovations. We’re working to recreate the magic of in vivo breast milk in vitro, offering parents a natural choice when breastfeeding isn’t an option.

80 similar entities Type: Startup Activities: healthtech deeptech Technologies: Bio sourced materials

Developing inobrodib (CCS1477), first-in-class p300/CBP inhibitor to treat specific cancers. Inobrodib is the first small molecule drug in the clinic targeting twin proteins p300 and CBP. It is formulated as a capsule taken orally. p300/CBP are twin (paralogue) acetyl transferases, and importantly, gene activating proteins that are known to play an important role in the progression of certain cancers. CellCentric’s pioneering drug is in Phase I/II clinical trials to evaluate its effectiveness to treat specific solid tumours, as well as haematological malignancies (blood cancers). These represent major clinical unmet needs, delivering a new therapy for people with cancer, who otherwise …

78 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Bringing innovative therapies to patients Draupnir Bio is a Danish biotechnology company driven by a deep commitment to scientific excellence and the desire to bring innovative therapies to patients in need. By harnessing the natural machinery of the lysosome, we are developing oral, small molecule degraders of extracellular pathogenic proteins – the next frontier of targeted protein degradation (TPD), a rapidly emerging field that exploits a cell’s own destruction machinery to tackle disease-causing proteins that have historically been highly challenging to target with conventional therapies. First-generation TPD approaches are exclusively limited to intracellular targets, leaving extracellular and membrane-bound proteins – …

77 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Seamless GMP Cell Separation: Healthier Cells, Better Therapies. Akadeum’s microbubble technology is the first GMP cell separation modality to solve all the challenges in the early steps of the cell therapy manufacturing process: time, cost, scalability, and performance. Microbubbles are flexible to integrate into any workflow and provide an increase in potency and persistence while enabling up to a 40% reduction in overall cell therapy manufacturing costs. Compatible with both centralized and decentralized manufacturing models, utilizing microbubbles for cell separation is the path to greater access and more cost-effective therapeutics. Healthier Cells. Better Therapies. Microbubble Cell Separation, Cell Therapy, and …

59 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

At Swalife Biotech, we are at the forefront of developing next-generation therapies for cancer and chronic diseases. Our research is rooted in the discovery of five novel bioactive alkaloids from plants, aimed at synthesizing compounds that target key mechanisms in skin and breast cancer. We leverage cutting-edge technologies such as network pharmacology and AI to enhance our understanding and development of drug therapies. Our alkaloids have shown promising results in inhibiting the DNA Damage Response (DDR) pathway, crucial in preventing drug resistance and cancer cell survival. Our innovative approach not only targets cancer but also extends to managing chronic diseases, …

111 similar entities Type: Startup Activities: biotech deeptech Technologies: Bio sourced materials

We're on a mission to cure blindness with our transformational platform of advanced therapies. Aurion Biotech, Inc. (Aurion Biotech) is a clinical stage biotech company, developing a transformational platform of advanced therapies to cure blindness. Our first candidate is for the treatment of corneal endothelial disease, and one of the first clinically validated cell therapies for corneal care. CAUTION: New Drug—Limited by Federal (or United States) law to investigational use.

73 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Make​ your Own Neuronal Network At MicroBrain Biotech, our mission is to revolutionize drug development by embracing ethical and cruelty-free practices, putting humanity at the center of our work, and relentlessly pursuing groundbreaking discoveries. We are committed to creating innovative solutions that improve the quality of life for patients and their families, while treating all living beings with compassion and respect. Through collaboration, scientific excellence, and a commitment to sustainability, we aim to leave a lasting positive impact on the world of healthcare and beyond.

143 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology

Idea Therapeutics is a Spanish biotech start-up focused on advanced therapy medicinal products (ATMPs), aiming to address diseases with limited therapeutic options. Our current research projects focus on regenerative medicine and immunology, with a long-term vision of expanding into other high-impact therapeutic areas such as oncology. At Idea Tx, we believe in the transformative power of science. Our mission is to investigate and develop disruptive ideas into new research lines in the field of ATMPs. We follow an open innovation model through strategic partnerships with leading public and private hospitals and research centers, integrating the entire value chain and driving …

74 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A Joint Venture with Unilever PLC, creating a world free of harmful Biofilms though novel technology inspired by Nature. Were are a Joint Venture initiative with Unilever PLC formed in late 2019 with exclusive rights to the commercialise a new and novel technology based on furanone chemistry that inhibits Biofilms. Inspired by the biology of red seaweed, this single molecule platform offers a sustainable low-toxicity alternative to existing biocides. It has activity against bacteria by blocking quorum sensing and communication through multiple identified molecular targets in the bacteria, but is also effective against moulds and algae making this a unique …

63 similar entities Type: Startup Activities: deeptech biotech Technologies: Bio sourced materials

Stellate Therapeutics develops innovative microbiome-derived small molecules to treat neurodegenerative diseases. Stellate Therapeutics is a pre-clinical stage start-up company developing innovative microbiome-derived small molecules to treat neurodegenerative diseases. We utilize the microbiome for our drug portfolio and our research focuses on the gut-brain axis. Due to millions of years of co-evolution, complex metabolic interactions exist between humans and their gut bacteria and Stellate has uncovered a unique set of metabolites that are produced by the microbiome and are involved in the maintenance of health. Our first drug will be a treatment for Parkinson’s disease.

74 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

CDMO Services (Research, Development and cGMP Manufacturing for Biologics) Bionova Scientific is a dynamic, full service, biologics Contract Development and Manufacturing Organization (CDMO) on a mission to deliver the highest quality process development and manufacturing services to biologic drug development companies around the world. Bionova’s renowned scientific expertise and dedication to its customers helps life changing therapies arrive to the market faster and more efficiently. At the heart of Bionova is a team of highly dedicated experts combining strong experience in cGMP biologics manufacturing and process development, with a technology-focused approach and a deep knowledge of the industry. From early …

60 similar entities Type: SMB Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

A Wholly Owned Subsidiary of Eli Lilly and Company Kelonia is pioneering a new wave of genetic medicines using its next generation gene delivery platform. The company’s simple and elegant cutting-edge in vivo gene delivery technology uses a few potent lentiviral vector-like particles to precisely and efficiently deliver in vivo genetic cargo to the desired target tissue, and only that tissue, every time. With an initial focus on developing transformational therapies for solid tumors and hematologic cancers, Kelonia is building a pipeline of genetic medicines for a wide range of diseases, with the bold goal of bringing genetic medicines to …

61 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Changing lives with next generation peptide therapeutics At Zealand Pharma, we are a Danish biotechnology company on a mission to change lives with next generation peptide medicines. In our effort to reach our goals, bonding is at the core of everything we do. Let it be discovering and developing the best new peptide drugs for patients, engaging with partners or connecting with each other. Ten drug candidates invented by Zealand Pharma have advanced into clinical development, of which two have reached the market. Our current pipeline of internal product candidates focuses on obesity, chronic inflammation, and certain rare diseases. Our …

186 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Reconcile the time of Research with the one of Medecine APTEΞUS was created to provide clinicians and their patients suffering from orphan diseases, an innovative service of clinical biology that perfectly meets the emerging challenge of individualized medicine. APTEΞUS is engaged in patient-centric discovery of individualized treatments. Our technology allows the testing of thousands of molecules directly on primary cells sampled from patient with inborn error of metabolism. We can rapidly identify molecules that specifically correct the very molecular defect of the patient and give him a new opportunity to be cured.

112 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Iterum Therapeutics plc is an Ireland-based clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives. These products are aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum’s first product is a novel anti-infective compound that has demonstrated potent in-vitro activity vs. a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. For more information on Iterum Therapeutics please visit www.iterumtx.com.

64 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Xbrane is a leading science based biosimilar developer of cost effective medicines with high unmet medical need Xbrane is a biopharmaceutical company specialized in high demand biosimilars and long acting injectables. We enable global health equality by bringing affordable drugs to treat underserved people suffering from critical diseases. Xbrane posses world leading expertise in developing true generics for injectable controlled release drugs and proprietary high-yield protein expression technology. Complex generics, Protein expression, Biosimilars, Controlled release, Strain development, and Formulation

112 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Our rational design approach in therapeutics offers a paradigm shift in disease, making the untreatable, treatable. We're pioneering a new era in drug design and development with rationally designed medicines leveraging human capabilities in advanced chemistry and biotech advancements. Our approach centers around biomimicy selectively targeting central cascades that drive disease. Our lead program is in development in kidney disease and has the potential to modify disease outcomes for millions of patients.

168 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Changing the way cancer is fundamentally treated. ELIAS Animal Health is a medical biotechnology company focused on advancing a pipeline of immunotherapies, including an adoptive cell therapy and an oncolytic virotherapy, for the treatment of canine cancers. The company’s therapeutic pipeline offers the prospect of improved clinical outcomes and the potential for fundamentally changing the way cancer is treated. Learn more at www.eliasanimalhealth.com. About ECI® The company's lead product, ELIAS Cancer Immunotherapy (ECI®), is the first-ever USDA-approved treatment for canine osteosarcoma, a deadly form of bone cancer in dogs. combines an autologous vaccine with cell therapy to target a patient’s …

69 similar entities Type: Startup Activities: pettech biotech healthtech deeptech Technologies: Synthetic Biology

Advancing Glycan Mediated Therapy GlycoEra is developing biologics to selectively target the root cause of many autoimmune diseases: a specific circulating protein (autoantibody). Our approach enables us to degrade targets rapidly, selectively, and deeply while avoiding broader dampening of the immune system. This offers many potential benefits over existing broad-spectrum immune-suppressing therapies, including an improved safety profile and the potential for earlier disease intervention – which could improve patient quality of life, limit long-term complications and lower overall healthcare costs. Our best-in-class, extracellular degrader BiNDTM platform (Biologic Natural Degrader), allows us to target and rapidly, deeply degrade any circulating protein …

208 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Bioceltix is changing the veterinary therapy standards. We develop innovative biopharmaceuticals based on stem cells. Bioceltix is a Wrocław-based and internationally oriented biotechnological company developing innovative, both stem cells and secretome based products, for companion animals. Our flagship technology for manufacturing biopharmaceuticals for veterinary use utilizes the therapeutic potential of allogeneic stem cells (one donor – many recipients). Owning a GMP production facility, we provide single technology for several species, diseases, and routes of administration. Our cutting-edge approach will allow the product to be batch-produced and ready for off-the-shelf sale. The veterinary medicines, based on the immunomodulatory mechanism of action …

231 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The Biosimilar Experts Who we are Formycon AG is a leading, independent developer of high-quality biosimilars, follow-on products of biopharmaceutical medicines. The company focuses on therapies in ophthalmology, immunology, immuno-oncology and other key disease areas, covering almost the entire value chain from technical development through clinical trials to approval by the regulatory authorities. For commercialization of its biosimilars, Formycon relies on strong, well-trusted and long-term partnerships worldwide. About Biosimilars: Since their introduction in the 1980s, biopharmaceutical drugs have revolutionized the treatment of serious and chronic diseases. By 2032, many of these drugs will lose their patent protection – including 45 …

85 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing first-in-class therapies designed to defeat chronic inflammation and fibrosis at the source. Our innovative therapeutic approach targets upstream amplifiers of disease offering potential treatments across a diverse array of therapeutic indications. Calluna Pharma is a clinical stage biotech company driven by a commitment to improve patient outcomes in diseases where existing treatments are sub-optimal. We believe in the power of immunology to push boundaries, challenge the status quo, and develop therapies that will make a real difference for people living with serious diseases.

202 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing new treatments to restore healthy mitochondrial metabolism in patients living with high-risk obesity. MitoRx is a biotech company targeting the restoration of healthy mitochondrial metabolism in high risk obesity. Our first-in-class small molecule asset, MTRX31, targets the elimination of ectopic fat from affected organs, in people with metabolically unhealthy obesity, by resetting mitochondrial function rather than suppressing appetite. This has the potential to deliver durable and higher quality weight loss with implications for lower risk of cardiovascular complications and other serious disease, as well as benefits for body composition and improved quality of life. mitochondrial disease, neuromuscular disease, biotech, …

58 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A breakthrough in healing, in the palm of your hand. Hard-to-heal wounds affect more than 50 million patients worldwide, creating a major clinical and economic burden on healthcare systems. Piomic Medical is a Swiss ETH Zurich startup, pioneering deep tissue regeneration through physical stimulation therapies. We are headquartered in Zurich with U.S. operations in Chicago. Our proprietary COMS® platform (Concurrent Optical and Magnetic Stimulation) delivers synergistic stimulation designed to modulate key regenerative pathways, including ion channel signaling, nitric oxide production, and mitochondrial activity, to support cellular metabolism and facilitate tissue repair. Our flagship device, the COMS® One Therapy System, is …

77 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

Developing Bioprinted Tissue Therapeutics to transform how we treat some of the most elusive diseases. Aspect Biosystems is a biotechnology company pioneering the development of a novel category of cellular medicines designed to replace or restore biological function and deliver curative therapies for some of the most elusive diseases. Aspect is developing these bioengineered cellular medicines by applying its full-stack tissue therapeutic platform, which integrates proprietary AI-powered bioprinting technology, therapeutic cells, hypoimmune cell engineering, and advanced biomaterials. Aspect is advancing its therapeutic pipeline across multiple endocrine and metabolic diseases, including diabetes and rare endocrine disorders. bioprinting, regenerative medicine, therapeutic development, …

64 similar entities Type: Startup Activities: deeptech biotech Technologies: 3D Printing New Materials Synthetic Biology

Facial & Body Remodeling Technology for Medical Aesthetics PB&B Ltd. is a specialty Swiss Life Sciences company founded by bioengineers working with plastic surgeons & dermatologists to test and bring to market a new patented injectable technology for the remodeling of soft tissues of the face & body. PBB-002 enhances adipocytes' volume with fatty acids, as to provide natural & longer-term results with the highest level of safety. PB&B’s patented technology aims to transform a fast growing, multi-billion-dollar facial aging & body remodeling markets with the next generation of injectables in Medical Aesthetics. Aesthetics, Facial rejuvenation, Breast augmentation, Buttock augmentation, …

69 similar entities Type: Startup Activities: healthtech biotech deeptech Technologies: Synthetic Biology

We Empower Cells In Vivo to Fight Diseases. EsoBiotec is a biotechnology company developing innovative therapeutics to fight cancer. Our mission is to empower the human body to tackle cancer by bringing in vivo engineering of cells to patients. We aim to develop cost-effective and off-the-shelf therapeutics and providing state-of-the-art cell therapies to maximise accessibility. Our disruptive approach holds the potential to transform the current standard of cell and gene therapies for cancer treatment. Gene therapy, Biotechnology, Oncology, Cell therapy, Cancer, in vivo engineering, virology, and Immunology

216 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Fighting chronic and fatal diseases Tirecat Health is a company developing a family of novel polymers with amazing potential in the healthcare field. We are propelled with purpose to fight chronic and fatal diseases affecting patients worldwide using our revolutionary technology to improve their quality of life. In order to make this purpose a reality, the company is preparing to move towards the clinical phase to demonstrate the astonishing results seen in preclinical trials.

300 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology